E210 - The PsychopharmaStahlogy Show: Potenti...

In this episode, Dr. Andy Cutler speaks with Dr. Thomas Schwartz about insomnia related to antidepressant discontinuation, including how rebound and withdrawal symptoms can emerge when tapering or stopping treatment. They review the underlying mechanisms, clinical risk factors, a ...  Show more

In this episode, Dr. Andy Cutler speaks with Dr. Holly Swartz about the critical role of sleep and circadian rhythms in bipolar disorder, including how sleep disturbance can function as both a symptom and trigger of mood episodes. They discuss how clinicians can better assess sle ...  Show more

Send us Fan MailThe path to FDA approved prescribable medicine has been a long and precarious one for psychedelics. However, recent reports by some of the major players in the psychedelic medicine space show promising results from clinical trials involving psilocybin and 5-MeO-DM ...  Show more

In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics. We explore the science and therapeutic po ...  Show more

In this episode, Joe interviews Josh Lipson, a Ph.D. candidate in clinical psychology at Columbia University, whose research explores the relationship between psychedelics, mystical experiences, and mental health. He discusses the complexities of studying psychedelics in real-wor ...  Show more

Send us Fan MailIn this episode of the Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison explore how psychedelic experiences might solicit false or maladaptive beliefs. Learn more about our podcast at https://numinusnetwork.com/learn/podcast/Learn more a ...  Show more